Bradley Foster & Sargent’s DexCom DXCM Stock Holding History

Bradley Foster & Sargent’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,531	Closed	-$221K	–	546
2025 Q2	$221K	Buy	+2,531	New	+$198K	﹤0.01%	515
2025 Q1	–	Sell	-2,639	Closed	-$205K	–	464
2024 Q4	$205K	Buy	+2,639	New	+$195K	﹤0.01%	456
2014 Q1	–	Sell	-32,000	Closed	-$283K	–	342
2013 Q4	$283K	Sell	32,000 -16,000	-33%	-$127K	0.02%	305
2013 Q3	$339K	Hold	48,000	–	–	0.02%	269
2013 Q2	$269K	Buy	+48,000	New	+$230K	0.02%	283

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bradley Foster & Sargent's DXCM Position: Q3 2025 in Review

Bradley Foster & Sargent sold out of DexCom (DXCM) in Q3 2025, closing a stake of 2,531 shares — an estimated $221K sold.

Bradley Foster & Sargent first reported a position in DXCM in Q2 2013 and held it in 5 quarters. The position peaked at $339K in Q3 2013. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Bradley Foster & Sargent reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Bradley Foster & Sargent sold 2,531 DexCom shares in Q3 2025, an estimated $221K.
Bradley Foster & Sargent first reported a position in DexCom in Q2 2013 and held it in 5 quarters.
Bradley Foster & Sargent's DexCom position peaked at $339K in Q3 2013.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Bradley Foster & Sargent's 13F filing for Q3 2025, filed 10 Nov 2025.